View Item 

Show simple item record

HIF‐1α and CA‐IX as predictors of locoregional control for determining the optimal treatment modality for early‐stage laryngeal carcinoma
dc.contributor.authorKwon, Oh Jinen_US
dc.contributor.authorPark, Jung Jeen_US
dc.contributor.authorKo, Gyung Hyucken_US
dc.contributor.authorSeo, Ji Hyunen_US
dc.contributor.authorJeong, Bae‐kwonen_US
dc.contributor.authorKang, Ki Munen_US
dc.contributor.authorWoo, Seung Hoonen_US
dc.contributor.authorKim, Jin Pyeongen_US
dc.contributor.authorHwa, Jeong Seoken_US
dc.contributor.authorCarey, Thomas E.en_US
dc.date.accessioned2015-04-02T15:12:38Z
dc.date.available2016-05-10T20:26:28Zen
dc.date.issued2015-04en_US
dc.identifier.citationKwon, Oh Jin; Park, Jung Je; Ko, Gyung Hyuck; Seo, Ji Hyun; Jeong, Bae‐kwon ; Kang, Ki Mun; Woo, Seung Hoon; Kim, Jin Pyeong; Hwa, Jeong Seok; Carey, Thomas E. (2015). "HIFâ 1α and CAâ IX as predictors of locoregional control for determining the optimal treatment modality for earlyâ stage laryngeal carcinoma." Head & Neck 37(4): 505-510.en_US
dc.identifier.issn1043-3074en_US
dc.identifier.issn1097-0347en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/110875
dc.description.abstractBackgroundThe purpose of this study was to examine the predictive value of hypoxia‐inducible factor (HIF)−1α, carbonic anhydrase (CA)‐IX, glucose transporter (GLUT)−1, cyclooxygenase (COX)−2, Ki‐67, and erythropoietin receptor (EPOR) as immunohistochemical markers for determining the optimal treatment modality for early stage laryngeal carcinoma.MethodsTissue samples from 42 early stage laryngeal carcinomas treated with radiotherapy alone were analyzed immunohistochemically for the expression of 6 markers. The Kaplan–Meier method, univariate and multivariate analyses, and the Cox proportional hazards model were used to analyze the associations between patient and tumor characteristics and immunohistochemical results, and locoregional control.ResultsIncreased expression of HIF‐1α and CA‐IX was significantly correlated with residual tumor; no correlations were observed for the other immunohistochemical markers.ConclusionHigh levels of HIF‐1α or CA‐IX expression were significantly correlated with residual tumor after radiotherapy for early stage laryngeal carcinomas. Alternative treatment modalities to primary radiotherapy should be considered for early stage laryngeal carcinomas showing high HIF‐1α or CA‐IX expression. © 2014 Wiley Periodicals, Inc. Head Neck 37: 505–510, 2015en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherlaryngeal carcinomaen_US
dc.subject.otherhypoxia‐inducible factor‐1αen_US
dc.subject.othercarbonic anhydrase IXen_US
dc.subject.otherglucose transporter‐1en_US
dc.subject.otherradiotherapyen_US
dc.titleHIF‐1α and CA‐IX as predictors of locoregional control for determining the optimal treatment modality for early‐stage laryngeal carcinomaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/110875/1/hed23620.pdf
dc.identifier.doi10.1002/hed.23620en_US
dc.identifier.sourceHead & Necken_US
dc.identifier.citedreferenceMatsumoto M, Komiyama K, Okaue M, et al. Predicting tumor metastasis in patients with oral cancer by means of the proliferation marker Ki67. J Oral Sci 1999; 41: 53 – 56.en_US
dc.identifier.citedreferenceJonathan RA, Wijffels KI, Peeters W, et al. The prognostic value of endogenous hypoxia‐related markers for head and neck squamous cell carcinomas treated with ARCON. Radiother Oncol 2006; 79: 288 – 297.en_US
dc.identifier.citedreferenceAebersold DM, Burri P, Beer KT, et al. Expression of hypoxia‐inducible factor‐1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911 – 2916.en_US
dc.identifier.citedreferenceZagórska A, Dulak J. HIF‐1: the knowns and unknowns of hypoxia sensing. Acta Biochim Pol 2004; 51: 563 – 585.en_US
dc.identifier.citedreferenceKaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor‐ and hypoxia‐marker carbonic anhydrase 9: a one transcription factor (HIF‐1) show? Biochim Biophys Acta 2009; 1795: 162 – 172.en_US
dc.identifier.citedreferenceMacheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654 – 662.en_US
dc.identifier.citedreferenceLi DW, Zhou L, Jin B, Xie J, Dong P. Expression and significance of hypoxia‐inducible factor‐1α and survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head Neck Surg 2013; 148: 75 – 81.en_US
dc.identifier.citedreferenceOhba S, Fujii H, Ito S, et al. Overexpression of GLUT‐1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. J Oral Pathol Med 2010; 39: 74 – 78.en_US
dc.identifier.citedreferenceHui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia‐inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595 – 2604.en_US
dc.identifier.citedreferenceEriksen JG, Overgaard J; Danish Head and Neck Cancer Study Group (DAHANCA). Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study. Radiother Oncol 2007; 83: 383 – 388.en_US
dc.identifier.citedreferenceLin PC, Lin YJ, Lee CT, Liu HS, Lee JC. Cyclooxygenase‐2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients. Oncol Lett 2013; 6: 733 – 739.en_US
dc.identifier.citedreferenceMorita Y, Hata K, Nakanishi M, Nishisho T, Yura Y, Yoneda T. Cyclooxygenase‐2 promotes tumor lymphangiogenesis and lymph node metastasis in oral squamous cell carcinoma. Int J Oncol 2012; 41: 885 – 892.en_US
dc.identifier.citedreferencePark BW, Park S, Park HS, et al. Cyclooxygenase‐2 expression in proliferative Ki‐67‐positive breast cancers is associated with poor outcomes. Breast Cancer Res Treat 2012; 133: 741 – 751.en_US
dc.identifier.citedreferenceAtula T, Hedström J, Ristimäki A, et al. Cyclooxygenase‐2 expression in squamous cell carcinoma of the oral cavity and pharynx: association to p53 and clinical outcome. Oncol Rep 2006; 16: 485 – 490.en_US
dc.identifier.citedreferenceGerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation‐associated human nuclear antigen defined by the monoclonal antibody Ki‐67. J Immunol 1984; 133: 1710 – 1715.en_US
dc.identifier.citedreferenceGerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation‐associated nuclear antigen that is defined by monoclonal antibody Ki‐67. Am J Pathol 1991; 138: 867 – 873.en_US
dc.identifier.citedreferenceLiu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations. Head Neck 2003; 25: 280 – 288.en_US
dc.identifier.citedreferenceKoo TR, Eom KY, Kang EY, et al. Prognostic value of the nodal ratio and ki‐67 expression in breast cancer patients treated with postmastectomy radiotherapy. J Breast Cancer 2013; 16: 274 – 284.en_US
dc.identifier.citedreferenceMontebugnoli L, Badiali G, Marchetti C, Cervellati F, Farnedi A, Foschini MP. Prognostic value of Ki67 from clinically and histologically ‘normal' distant mucosa in patients surgically treated for oral squamous cell carcinoma: a prospective study. Int J Oral Maxillofac Surg 2009; 38: 1165 – 1172.en_US
dc.identifier.citedreferenceGonzalez–Moles MA, Ruiz–Avila I, Gil–Montoya JA, Esteban F, Bravo M. Analysis of Ki‐67 expression in oral squamous cell carcinoma: why Ki‐67 is not a prognostic indicator. Oral Oncol 2010; 46: 525 – 530.en_US
dc.identifier.citedreferencePerisanidis C, Perisanidis B, Wrba F, et al. Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 2012; 41: 40 – 46.en_US
dc.identifier.citedreferenceMorais C, Johnson DW, Vesey DA, Gobe GC. Functional significance of erythropoietin in renal cell carcinoma. BMC Cancer 2013; 13: 14.en_US
dc.identifier.citedreferenceHenke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708 – 4713.en_US
dc.identifier.citedreferenceHarrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002; 7: 492 – 508.en_US
dc.identifier.citedreferenceHarrison LB, Shasha D, Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy: prognostic significance and treatment. Oncology 2002; 63 Suppl 2: 11 – 18.en_US
dc.identifier.citedreferenceMendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1–T2 glottic carcinomas. Cancer 2004; 100: 1786 – 1792.en_US
dc.identifier.citedreferenceHosokawa Y, Okumura K, Terashima S, Sakakura Y. Radiation protective effect of hypoxia‐inducible factor‐1α (HIF‐1α) on human oral squamous cell carcinoma cell lines. Radiat Prot Dosimetry 2012; 152: 159 – 163.en_US
dc.identifier.citedreferenceDouglas CM, Bernstein JM, Ormston VE, et al. Lack of prognostic effect of carbonic anhydrase‐9, hypoxia inducible factor‐1α and bcl‐2 in 286 patients with early squamous cell carcinoma of the glottic larynx treated with radiotherapy. Clin Oncol (R Coll Radiol) 2013; 25: 59 – 65.en_US
dc.identifier.citedreferenceRademakers SE, Hoogsteen IJ, Rijken PF, et al. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiother Oncol 2013; 108: 517 – 522.en_US
dc.identifier.citedreferenceParkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153 – 156.en_US
dc.identifier.citedreferenceBoring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7 – 26.en_US
dc.identifier.citedreferenceVaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381: 335 – 354.en_US
dc.identifier.citedreferenceBussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro‐regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003; 67: 3 – 15.en_US
dc.identifier.citedreferenceRockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009; 9: 442 – 458.en_US
dc.identifier.citedreferenceSchrijvers ML, van der Laan BF, de Bock GH, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA‐IX predict for local recurrence in stage T1‐T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008; 72: 161 – 169.en_US
dc.identifier.citedreferenceKoukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia‐activated tumor pathways of angiogenesis and pH regulation independent of anemia in head‐and‐neck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 67 – 71.en_US
dc.identifier.citedreferenceHirasawa N, Itoh Y, Naganawa S, et al. Multi‐institutional analysis of early glottic cancer from 2000 to 2005. Radiat Oncol 2012; 7: 122.en_US
dc.identifier.citedreferenceMoeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26: 241 – 248.en_US
dc.identifier.citedreferenceVaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225 – 239.en_US
dc.identifier.citedreferenceVordermark D, Brown JM. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol 2003; 179: 801 – 811.en_US
dc.identifier.citedreferenceAlvarez Marcos CA, Llorente Pendás JL, Franco Gutiérrez V, et al. Tumour recurrence in squamous head and neck cancer [in Spanish]. Acta Otorrinolaringol Esp 2007; 58: 156 – 163.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed23620.pdf
Size:
251.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.